Affordable medicines, preventing shortages and a climate-neutral industry – Parliament presses for a new EU pharmaceutical policy. During the plenary session in November 2021, the European Parlimanet set out a series of recommendations for the update of the EU’s pharmaceutical legislation. Faster access In 2019, the European Medicines Agency (EMA) authorised 103 orphan drugs – which are […]
Commission proposes a progressive roll-out of the new In Vitro Diagnostic Medical Devices Regulation
The European Commission has proposed a progressive roll-out of the new In Vitro Diagnostic Medical Devices Regulation to prevent disruption in the supply of these essential healthcare products. The unprecedented challenges of the COVID-19 pandemic have diverted resources from Member States, health institutions and economic operators towards addressing the crisis, thereby hampering the capacity to […]
H2020. Restricted Call to maximise impact of IMI2 JU objectives and scientific priorities
A major challenge in life sciences, in particular within the medicines development process, is the scale of the investment required, the stepwise approach, very long development timelines and the successful involvement of relevant stakeholders. Certain IMI2 JU topics, launched under IMI2 JU Calls for proposals that are now closed, anticipated in their corresponding work plans […]
MEPs want more role for EU in improving public health
In a debate on public health strategy, MEPs pointed out that the pandemic has shown that the EU needs better tools to deal with health emergencies. MEPs discussed the issue with Health Commissioner Stella Kyriakides and the German Presidency of the Council, before voting on Friday on a resolution on the public health strategy following […]